Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026GlobeNewsWire · Oct 6, 2026
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 10, 2026
Reviewing Galectin Therapeutics (NASDAQ:GALT) & SQZ Biotechnologies (NYSE:SQZ)Defense World · Aug 31, 2026
20 stocks likely to lose money even if the bull market continuesMarket Watch · Aug 27, 2026
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving Average – Here’s What HappenedDefense World · Aug 27, 2026
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Aug 14, 2026Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.09 | -$0.14 | Miss |
| May 15, 2026 | -$0.06 | -$0.08 | Miss |
| Mar 31, 2026 | -$0.10 | -$0.08 | Beat |
| Nov 14, 2025 | -$0.11 | -$0.13 | Miss |
| Aug 14, 2025 | -$0.16 | -$0.12 | Beat |
| May 15, 2025 | -$0.20 | -$0.15 | Beat |